Company profile
Forte Biosciences, Inc.
Pipeline1 asset
- FB102FB102 / CD122 / monoclonal antibody / Autoimmune and autoimmune-related diseasesCeliac diseasePhase 2Topline results expected in 2026; U.S. arm included after FDA IND approvalUnited StatesVitiligoPhase 1bTopline results expected in 1H 2026Alopecia areataPhase 1bData readout expected in 2026